Olipass Receives USD 353,995 from Vanda Pharmaceuticals for Joint R&D - Modest Positive Cash Inflow
Olipass disclosed a correction that it received USD 353,995 (approx. 470 million KRW) from Vanda Pharmaceuticals under a joint R&D agreement for a new drug. This amount exceeds 10% of 2022 annual sales (approx. 2.3 billion KRW), making it subject to mandatory disclosure, but was initially withheld at Vanda's request and now released after the withholding period expired.
The received amount is recognized as R&D revenue, dated April 3, 2023, based on the invoice date. Although small, it is recognized as revenue rather than non-operating income, positively impacting profitability.
The amount represents only about 0.35% of the current market cap (134.1 billion KRW), so the direct impact on stock price is limited. However, it signals continued collaboration with Vanda and potential future milestones.
[AI Summary]Olipass's receipt of R&D fees from Vanda is a small but positive event, recognized as revenue and demonstrating ongoing partnership with a global pharma, which may slightly boost investor sentiment, but the scale is too minor to materially change the stock price outlook.
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related To Investment Decision (Receipt Of R&D Expenses For Joint Research And Development Of New Drug)